About this trial
The goal of this clinical trial is to compare a novel tactic for mitigating reinstatement compared to the current standard of care approach using a translational-treatment model. The main questions it aims to answer are:
1. how well does progressive ratio training mitigate response-dependent reinstatement compared to the standard of care approach? 2. how well does progressive ratio training mitigate response-independent reinstatement compared to the standard of care approach?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Boys and girls from ages 6 to 21
Engage in problem behavior
Diagnosis of some type of intellectual and developmental disability
Disqualifiers
Not meeting the inclusion criteria
Trial design
Parallel
Treatments tested in this trial
Progressive Ratio Training (PRT)
BehavioralProgressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16, -32, etc.
Differential Reinforcement of Alternative (DRA) Behavior with Extinction
BehavioralIn DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
Treatment groups
Trial outcomes
Primary outcomes
Treatment Effectiveness
The number of individuals for whom treatment remains effective (either progressive ratio training or current standard-of-care), which investigators will determine by comparing the mean rate of responding in baseline and subsequent conditions (Treatment and Reinstatement Tests 1 and 2). If investigators find at least an 80% reduction in target behavior in a condition (a standard clinical target for problem behavior), they will conclude that the treatment is effective (or remains effective).
Secondary outcomes
Proportional and Comparative Effectiveness
The proportional and comparative effectiveness of the treatments, which investigators will determine from the mean rate of behavior in Phase 2 Treatment and the treatments during Phase 3 Reinstatement Tests (with progressive-ratio training and the standard-of-care approach), and determine the difference in percent reduction between treatment and the reinstatement tests. This second measure is preliminary: no pilot data speak to what may be observed. However, these data are likely to be important to future research.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Oakland University
Lead sponsor
Auburn University
Collaborator